Brief: Sino Biopharmaceutical Says Application For Phase II Clinical Trial On LM-24C5 "CEACAM5/4-1BB Bispecific Antibody" Approved By China NMPA
07/08/2025 14:45
Aug 7 (Reuters) - Sino Biopharmaceutical Ltd 1177.HK: APPLICATION FOR PHASE II CLINICAL TRIAL ON LM-24C5 "CEACAM5/4-1BB BISPECIFIC ANTIBODY" APPROVED BY CHINA NMPA Further company coverage: 1177.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sino Biopharmaceutical
See all newsHong Kong stocks end higher on pharma, tech gains
Hong Kong stocks climb, led by pharmaceutical, tech stocks
Brief: Sino Biopharmaceutical Says China's CDE Accepts NDA For TQH2722 Injection
Brief: Sino Biopharmaceutical China CDE Accepts New Drug Application For TQB2102 Injection
Sino Biopharmaceutical climbs on plan to raise stake in core unit